Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

Moderna, Inc.; Entrada Therapeutics ... duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX) today revealed Phase 3 data on its investigational cystic fibrosis (CF) drug,... ByInvesting.com • Sep 26, 2024 Vertex ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia. A Watertown biotech is ...

Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc ... Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation software. S&P 500 components Fortinet and Boston ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced ... patients with SCD and TDT. BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq ...

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) is set to present pivotal Phase 3 data on suzetrigine, an investigational non-opioid pain signal... ByInvesting.com • Oct ...